<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269267</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00023447</org_study_id>
    <nct_id>NCT02269267</nct_id>
  </id_info>
  <brief_title>The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)</brief_title>
  <official_title>The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barbara Ann Karmanos Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Duke Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weill Medical College of Cornell University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>H. Lee Moffitt Cancer Center and Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical College of Wisconsin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a non-randomized, prospective, single-group longitudinal study. The purpose of this
      study is to improve the decision making process used by physicians and patients when they are
      considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, prospective, single-group longitudinal study. The overall objective
      is to improve decision making for TKI discontinuation in eligible chronic myelogenous
      leukemia (CML) patients. Patients with CML on treatment with imatinib, dasatinib, nilotinib,
      or bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep
      (&gt; 4 log reduction) molecular response (&gt;MR4) defined as p210 (bcr-abl) fusion protein
      (BCR-ABL) &lt; 0.01%, for at least two years. The study will closely monitor patients using
      standard real-time Quantitative Polymerase Chain Reaction (RQ-PCR) testing for molecular
      recurrence, testing them monthly for six months, then every other month until 24 months, and
      then quarterly until 36 months. Concurrently, the study will assess a wide range of
      patient-reported outcomes (PROs) before stopping TKIs and after discontinuation in
      conjunction with Polymerase Chain Reaction (PCR) testing, though at fewer time points,
      utilizing online and/or phone questionnaires. Patients who have molecular CML recurrence
      based on RQ-PCR will restart imatinib, dasatinib, nilotinib, or bosutinib and will continue
      to be monitored for disease status and health status until the end of the study.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with CML who develop molecular recurrence after discontinuing TKIs</measure>
    <time_frame>1, 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 27, 30, 33, 36 months</time_frame>
    <description>The number of patients who develop molecular recurrence after discontinuing TKIs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-reported health status related to fatigue of patients before and after stopping TKIs.</measure>
    <time_frame>Before and 3 years stopping TKIs.</time_frame>
    <description>Patient-reported health status of fatigue using the Patient-Reported Outcomes Measurement Information System (PROMIS) scales.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-reported health status related to depression of patients before and after stopping TKIs.</measure>
    <time_frame>Before and 3 years stopping TKIs.</time_frame>
    <description>Patient-reported health status of depression using the Patient-Reported Outcomes Measurement Information System (PROMIS) scales.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-reported health status related to sleep of patients before and after stopping TKIs.</measure>
    <time_frame>Before and 3 years stopping TKIs.</time_frame>
    <description>Patient-reported health status of sleep using the Patient-Reported Outcomes Measurement Information System (PROMIS) scales.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-reported health status related to GI symptoms of patients before and after stopping TKIs.</measure>
    <time_frame>Before and 3 years stopping TKIs.</time_frame>
    <description>Patient-reported health status of GI symptoms using the Patient-Reported Outcomes Measurement Information System (PROMIS) scales.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-reported health status related to anxiety of patients before and after stopping TKIs.</measure>
    <time_frame>Before and 3 years stopping TKIs.</time_frame>
    <description>Patient-reported health status of anxiety symptoms using the Patient-Reported Outcomes Measurement Information System (PROMIS) scales.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-reported health status related to physical function of patients before and after stopping TKIs.</measure>
    <time_frame>Before and 3 years stopping TKIs.</time_frame>
    <description>Patient-reported health status of physical function symptoms using the Patient-Reported Outcomes Measurement Information System (PROMIS) scales.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-reported health status related to pain of patients before and after stopping TKIs.</measure>
    <time_frame>Before and 3 years stopping TKIs.</time_frame>
    <description>Patient-reported health status of pain symptoms using the Patient-Reported Outcomes Measurement Information System (PROMIS) scales.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-reported health status related to social function of patients before and after stopping TKIs.</measure>
    <time_frame>Before and 3 years stopping TKIs.</time_frame>
    <description>Patient-reported health status of social function using the Patient-Reported Outcomes Measurement Information System (PROMIS) scales.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-reported health status related to sexual function of patients before and after stopping TKIs.</measure>
    <time_frame>Before and 3 years stopping TKIs.</time_frame>
    <description>Patient-reported health status of sexual function using the Patient-Reported Outcomes Measurement Information System (PROMIS) scales.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-reported health status related to social isolation of patients before and after stopping TKIs</measure>
    <time_frame>Before and 3 years stopping TKIs.</time_frame>
    <description>Patient-reported health status of social isolation using the Patient-Reported Outcomes Measurement Information System (PROMIS) scales.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-reported health status related to cognitive function of patients before and after stopping TKIs.</measure>
    <time_frame>Before and 3 years stopping TKIs.</time_frame>
    <description>Patient-reported health status of cognitive function using the Patient-Reported Outcomes Measurement Information System (PROMIS) scales.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-reported health status.</measure>
    <time_frame>Before and 3 years stopping TKIs.</time_frame>
    <description>In outcomes two through 12, if the PROMIS scale cannot be used, then the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) -CML Symptom Burden scale will be used.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">173</enrollment>
  <condition>Leukemia, Myeloid, Chronic</condition>
  <arm_group>
    <arm_group_label>Discontinuation of TKI medication</arm_group_label>
    <description>Patients with CML on treatment with imatinib, dasatinib, nilotinib, or bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (&gt; 4 log reduction) molecular response (&gt;MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) &lt; 0.01%, for at least two years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stopping their TKI</intervention_name>
    <description>Patients with CML on treatment with imatinib, dasatinib, nilotinib, or bosutinib and are in confirmed deep molecular response will stop their TKI. Confirmed deep (&gt; 4 log reduction) molecular response (&gt;MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) &lt; 0.01%, for at least two years. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.</description>
    <arm_group_label>Discontinuation of TKI medication</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with CML on treatment with imatinib, dasatinib, nilotinib, or bosutinib and are in
        confirmed deep molecular response will stop their TKI. Confirmed deep (&gt; 4 log reduction)
        molecular response (&gt;MR4) defined as p210 (bcr-abl) fusion protein (BCR-ABL) &lt; 0.01%, for
        at least two years.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 or older at time of study entry

          2. Willing and able to give informed consent

          3. Diagnosed with CML in chronic phase and have either the b3a2 (e14a2) or b2a2 (e13a2)
             variants that give rise to the p210 BCR-ABL protein

          4. Currently taking imatinib, dasatinib, nilotinib or bosutinib

          5. Patient has been on TKI therapy for at least 3 years

          6. Documented BCR-ABL &lt;0.01% (&gt;MR4 i.e. &gt;4 log reduction) or undetectable BCR-ABL by PCR
             for at least 2 years according to the patient's local lab

          7. Documented BCR-ABL &lt;0.01% (&gt;MR4 i.e. &gt;4 log reduction) or undetectable BCR-ABL at
             least 3 times prior to screening according to the patient's local lab

          8. Two (2) Screening PCRs have been completed and both results are &lt; 0.01% (&gt;MR4 i.e &gt; 4
             log reduction) by central lab

          9. Has been on any number of TKIs, but has not been resistant to any TKI (changes made
             for intolerance are allowed)

         10. Patient has been compliant with therapy per treating physician

        Exclusion Criteria:

          1. Prior hematopoietic stem cell transplantation

          2. Poor compliance with taking TKI

          3. Unable to comply with lab appointments schedule and PRO assessments

          4. Life expectancy less than 36 months

          5. Patients who have been resistant to previous TKI therapy are not eligible

          6. Pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ehab Atallah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathryn Flynn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helen Diller Family Comprehensive Cancer Center University of California</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffit Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago Medicine Comprehensive Cancer Center at Silver Cross</name>
      <address>
        <city>New Lenox</city>
        <state>Illinois</state>
        <zip>60451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center (Satellite site of Dana Farber)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute of Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132-2408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Froedtert Hospital &amp; Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 8, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical College of Wisconsin</investigator_affiliation>
    <investigator_full_name>Ehab L Atallah</investigator_full_name>
    <investigator_title>Associate Professor (Principal Investigator)</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tin Fluorides</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

